Zacks: Analysts Expect vTv Therapeutics Inc (NASDAQ:VTVT) Will Post Earnings of -$0.11 Per Share

Equities analysts predict that vTv Therapeutics Inc (NASDAQ:VTVT) will announce earnings per share (EPS) of ($0.11) for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for vTv Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.06) and the lowest estimate coming in at ($0.16). vTv Therapeutics posted earnings of ($0.06) per share in the same quarter last year, which suggests a negative year-over-year growth rate of 83.3%. The company is expected to report its next earnings report on Thursday, November 14th.

According to Zacks, analysts expect that vTv Therapeutics will report full-year earnings of ($0.53) per share for the current financial year. For the next fiscal year, analysts forecast that the firm will report earnings of ($0.43) per share, with EPS estimates ranging from ($0.60) to ($0.25). Zacks’ earnings per share averages are a mean average based on a survey of research analysts that cover vTv Therapeutics.

vTv Therapeutics (NASDAQ:VTVT) last released its earnings results on Wednesday, July 31st. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.11) by $0.02. The business had revenue of $1.83 million for the quarter, compared to analyst estimates of $1.63 million.

Several research firms have issued reports on VTVT. HC Wainwright reiterated a “buy” rating and set a $5.00 target price on shares of vTv Therapeutics in a research report on Friday, August 16th. Zacks Investment Research cut vTv Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. ValuEngine upgraded vTv Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, October 2nd. Finally, Northland Securities set a $8.00 price target on vTv Therapeutics and gave the stock a “buy” rating in a report on Wednesday, September 18th.

NASDAQ VTVT traded up $0.04 on Monday, hitting $1.51. 312,568 shares of the company’s stock were exchanged, compared to its average volume of 790,909. The firm’s 50-day moving average price is $1.43 and its two-hundred day moving average price is $1.47. vTv Therapeutics has a fifty-two week low of $1.00 and a fifty-two week high of $4.59. The firm has a market cap of $81.74 million, a price-to-earnings ratio of -2.19 and a beta of -3.61.

In other news, major shareholder Ronald O. Perelman purchased 1,369,863 shares of the stock in a transaction that occurred on Friday, September 27th. The shares were acquired at an average price of $1.46 per share, for a total transaction of $1,999,999.98. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Ronald O. Perelman purchased 50,000 shares of the stock in a transaction that occurred on Thursday, August 22nd. The stock was purchased at an average price of $1.38 per share, for a total transaction of $69,000.00. The disclosure for this purchase can be found here. In the last 90 days, insiders purchased 2,180,924 shares of company stock worth $3,273,751. Insiders own 1.70% of the company’s stock.

An institutional investor recently raised its position in vTv Therapeutics stock. BlackRock Inc. increased its position in vTv Therapeutics Inc (NASDAQ:VTVT) by 25.7% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 65,031 shares of the biotechnology company’s stock after acquiring an additional 13,305 shares during the period. BlackRock Inc. owned approximately 0.12% of vTv Therapeutics worth $93,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 1.64% of the company’s stock.

vTv Therapeutics Company Profile

vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase II/III clinical trials for the treatment of mild Alzheimer's disease.

Featured Story: Example of operating income, EBIT and EBITDA

Get a free copy of the Zacks research report on vTv Therapeutics (VTVT)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with's FREE daily email newsletter.